TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24510115

Group type: EXPERIMENTAL
Intervention: Female patients undergoing PCI
Number of subjects: 6218
Study: 24510638

Group type: EXPERIMENTAL
Intervention: DAPT interruption for 1 month
Number of subjects: 4896

Group type: EXPERIMENTAL
Intervention: DAPT interruption for >1-12 months
Number of subjects: 4896

Group type: COMPARATOR
Intervention: No DAPT interruption
Number of subjects: 4896

Group type: EXPERIMENTAL
Intervention: DAPT interruption for 1 month (long interruptions)
Number of subjects: 4896

Group type: EXPERIMENTAL
Intervention: DAPT interruption for >1-12 months (long interruptions)
Number of subjects: 4896

Group type: COMPARATOR
Intervention: Continuous DAPT
Number of subjects: 4896
Study: 24512954

Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m² on days 1, 4, 8, and 11 of a 21-day cycle
Number of subjects: 20
Study: 24513880

Group type: EXPERIMENTAL
Intervention: Coronary artery calcium (CAC) imaging by unenhanced computed X-ray tomography (CT)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: CAC = 0
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Patients with CAC >400 Au
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Patients with low pre-test probability of CAD and zero CAC
Number of subjects: 300
Study: 24515353

Group type: EXPERIMENTAL
Intervention: Healthy Buddies lesson plans
Number of subjects: 647

Group type: COMPARATOR
Intervention: Regular curriculum
Number of subjects: 647
Study: 24515598

Group type: EXPERIMENTAL
Intervention: Echocardiogram-derived measures
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Echocardiogram-derived measures in pure PAH phenotypes
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Bland-Altman analyses
Number of subjects: 21
Study: 24516013

Group type: EXPERIMENTAL
Intervention: R (rituximab) 375 mg/m(2) once per week for 4 weeks
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: R + MR (rituximab plus maintenance rituximab) administered once every 6 months for 2 years
Number of subjects: 39

Group type: COMPARATOR
Intervention: R (rituximab)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: R + MR (rituximab plus maintenance rituximab)
Number of subjects: 39
Study: 24516026

Group type: EXPERIMENTAL
Intervention: Intravenous pegaspargase at 2,000 IU/m(2) per dose, administered in six doses with intervals longer than 4 weeks
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Intravenous pegaspargase
Number of subjects: 51
Study: 24517219

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin G (IVIG) therapy (0.4 g kg(-1) day(-1) for 5 days)
Number of subjects: 156
Study: 24517388

Group type: EXPERIMENTAL
Intervention: Participants with SAD during the Beliefs task
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Participants with SAD during reappraising faces
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Participants with SAD during reappraising criticism
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Participants with SAD during reappraising beliefs
Number of subjects: 54

Group type: COMPARATOR
Intervention: Healthy controls (HC) during the Beliefs task
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both groups during the Faces and Criticism tasks
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: DMPFC activity in both groups
Number of subjects: 54
Study: 24517417

Group type: EXPERIMENTAL
Intervention: 300IR birch pollen sublingual solution
Number of subjects: 574

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 574
Study: 24517865

Group type: EXPERIMENTAL
Intervention: High-resolution anorectal manometry (HR-ARM)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Standard barostat
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: RBB
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: HR-ARM
Number of subjects: 26

Group type: COMPARATOR
Intervention: Elastic balloon measurements
Number of subjects: 26
Study: 24519196

Group type: EXPERIMENTAL
Intervention: Transdermal nanostructured formulation of progesterone (10%) combined with estriol (0.1%) + estradiol (0.25%)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Transdermal nanostructured formulation of progesterone and estrogens
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy
Number of subjects: 66
Study: 24519328

Group type: EXPERIMENTAL
Intervention: Liver stiffness measurement (LSM)
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: FIB-4
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: Baseline LSM (bLSM)
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: bLSM <7 kPa
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: Increase (≥ 1 kPa/year) in 7-14 kPa bLSM
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: Decrease (≤ 0 kPa/year) in ≥ 14 kPa bLSM
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: Increase (>0 kPa/year) in ≥ 14 kPa bLSM
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: Baseline and delta FIB-4
Number of subjects: 1025
Study: 24519427

Group type: EXPERIMENTAL
Intervention: PixR-NP cluster test (CT)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: PixR-NP single threshold test (STT)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: PixR-P single threshold test (STT)
Number of subjects: 267

Group type: COMPARATOR
Intervention: statistic image mapping (SIM)
Number of subjects: 267
Study: 24519964

Group type: EXPERIMENTAL
Intervention: PROgmatic trial management system
Number of subjects: 0
Study: 24520093

Group type: EXPERIMENTAL
Intervention: MAGE-A3 peptide vaccine combined with Poly-ICLC (Hiltonol), granulocyte macrophage colony-stimulating factor (GM-CSF) ± montanide
Number of subjects: 27
Study: 24520094

Group type: EXPERIMENTAL
Intervention: Vaccine containing GD2 and GD3 (30 μg each) and OPT-821 (150 μg/m²) with β-glucan (40 mg/kg/day, 14 days on/14 days off)
Number of subjects: 15
Study: 24520446

Group type: EXPERIMENTAL
Intervention: hMG
Number of subjects: 80

Group type: COMPARATOR
Intervention: rFSH
Number of subjects: 80
Study: 24520818

Group type: EXPERIMENTAL
Intervention: MeTree (patient facing family history assessment tool)
Number of subjects: 1184

Group type: EXPERIMENTAL
Intervention: Talking with family members before using MeTree
Number of subjects: 1184
Study: 24521776

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20 mg/d)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fluvastatin (80 mg/d)
Number of subjects: 12
Study: 24522441

Group type: EXPERIMENTAL
Intervention: Fried food consumption
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Total fat intake
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: >35% of daily energy intake from fat
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Available carbohydrate intake
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Frequent consumption of soda
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Daily fiber intake
Number of subjects: 74
Study: 24522445

Group type: EXPERIMENTAL
Intervention: Harris-Benedict equation, Mifflin-St Jeor equation, Owen equation, and 6 questions from the revised ALS Functional Rating Scale (ALSFRS-R)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Web-based calculator using the Rosenbaum equation and the same 6 questions from the ALSFRS-R
Number of subjects: 80
Study: 24522446

Group type: EXPERIMENTAL
Intervention: 1% linoleic acid (LA) emulsion
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control emulsion
Number of subjects: 59
Study: 24522447

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids intake
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Saturated fatty acids (SFAs) intake
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Added sugar intake
Number of subjects: 52
Study: 24523212

Group type: EXPERIMENTAL
Intervention: Xenodiagnosis using Ixodes scapularis larvae
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Xenodiagnosis
Number of subjects: 36
Study: 24523241

Group type: EXPERIMENTAL
Intervention: Plerixafor (0.01 to 0.02 mg/kg, subcutaneously, twice daily for 6 months)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Plerixafor (0.01 to 0.02 mg/kg, subcutaneously, twice daily for 6 months) in combination with imiquimod
Number of subjects: 3
Study: 24523869

Group type: EXPERIMENTAL
Intervention: Driving performance assessment using a dual-brake vehicle during a 40-minute driving task.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Visual exploration ability assessed through eye movements recorded by a mobile eye tracker.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Head movements assessment in relation to driving test outcomes.
Number of subjects: 30
Study: 24524285

Group type: EXPERIMENTAL
Intervention: Weight-reduction program including daily caloric restriction and exercise for 12 weeks
Number of subjects: 36
Study: 24524452

Group type: EXPERIMENTAL
Intervention: Hypothermia treatment for neonatal hypoxic-ischemic encephalopathy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 24524662

Group type: EXPERIMENTAL
Intervention: Caregivers associated with the research site in the Northwest
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Employed caregivers
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Increasing physical quality of life
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Younger female caregivers
Number of subjects: 433
Study: 24524773

Group type: EXPERIMENTAL
Intervention: Cheilectomy
Number of subjects: 8
Study: 24525446

Group type: EXPERIMENTAL
Intervention: Theophylline/corticosteroid combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 24525449

Group type: EXPERIMENTAL
Intervention: BODE index 0-2
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: BODE index 3-4
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: BODE index 5-6
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: BODE index 7-10
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: BODE index
Number of subjects: 191
Study: 24525531

Group type: EXPERIMENTAL
Intervention: Automatic telephonic assessment (ATA) system
Number of subjects: 444
Study: 24526575

Group type: EXPERIMENTAL
Intervention: Bortezomib plus irinotecan (1.3 mg/m² days 1, 4, 8, 11; 125 mg/m² days 1, 8 every 21 days)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Bortezomib alone (as second line therapy)
Number of subjects: 41
Study: 24527254

Group type: EXPERIMENTAL
Intervention: Post-exposure prophylaxis (PEP) with tenofovir/emtricitabine (Truvada)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Contingency management (CM) behavioral intervention targeting reductions in methamphetamine use
Number of subjects: 53
Study: 24527713

Group type: EXPERIMENTAL
Intervention: Subjects with 25OHD status of 20 ng/mL or greater
Number of subjects: 1824

Group type: COMPARATOR
Intervention: Subjects with plasma 25OHD less than 20 nmol/L
Number of subjects: 1824

Group type: EXPERIMENTAL
Intervention: Overweight/obese subjects with 25OHD status of 20 ng/mL or greater
Number of subjects: 1824

Group type: EXPERIMENTAL
Intervention: Normal weight subjects with 25OHD status of 20 ng/mL or greater
Number of subjects: 1824

Group type: EXPERIMENTAL
Intervention: Vitamin D-replete population
Number of subjects: 1824
Study: 24527718

Group type: EXPERIMENTAL
Intervention: Obese participants
Number of subjects: 77

Group type: COMPARATOR
Intervention: Healthy participants
Number of subjects: 77
Study: 24528219

Group type: EXPERIMENTAL
Intervention: Tositumomab and iodine(131)-tositumomab (TST/I(131)-TST)
Number of subjects: 93
Study: 24528505

Group type: EXPERIMENTAL
Intervention: Home Dialysis Virtual Ward (HDVW) intervention with weekly clinician-led telephone interviews for 2 weeks until VW discharge.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home Dialysis Virtual Ward (HDVW) intervention.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Home Dialysis Virtual Ward (HDVW) re-hospitalization rate.
Number of subjects: 0
Study: 24528907

Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 24529158

Group type: EXPERIMENTAL
Intervention: Gene Expression Score (GES)
Number of subjects: 610
Study: 24529163

Group type: EXPERIMENTAL
Intervention: Infliximab 3 mg/kg plus methotrexate (MTX) for 14 weeks
Number of subjects: 662
Study: 24529291

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (ramipril), specific dosage and duration not mentioned.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Support from clinical trial experts, ethics committee, public funding, medical society, and university sponsorship.
Number of subjects: 0
Study: 24529936

Group type: EXPERIMENTAL
Intervention: 2-stent strategy in non-LM bifurcation group
Number of subjects: 2897

Group type: EXPERIMENTAL
Intervention: 2-stent strategy in LM bifurcation group
Number of subjects: 2897
Study: 24530759

Group type: EXPERIMENTAL
Intervention: ATG induction
Number of subjects: 84
Study: 24530775

Group type: EXPERIMENTAL
Intervention: Regular physical activity measured in counts/minute using accelerometer (Actigraph GT3X) worn for seven days
Number of subjects: 1365
Study: 24530971

Group type: EXPERIMENTAL
Intervention: Myeloablative (131)I-tositumomab with fludarabine and ASCT
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Fludarabine (up to 210 mg/m2)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Myeloablative (131)I-tositumomab
Number of subjects: 36
Study: 24531331

Group type: EXPERIMENTAL
Intervention: High-risk SIHD (n=1,066)
Number of subjects: 4204

Group type: EXPERIMENTAL
Intervention: Low-risk SIHD (n=531)
Number of subjects: 4204
Study: 24531544

Group type: EXPERIMENTAL
Intervention: Metformin treatment; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AMPK activators (including metformin); specific dosage and duration not mentioned.
Number of subjects: 0
Study: 24531550

Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation (HSCT)
Number of subjects: 0
Study: 24531685

Group type: EXPERIMENTAL
Intervention: Uncalibrated pulse contour analysis (UPCA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Transpulmonary thermodilution (TPTD)
Number of subjects: 20
Study: 24532680

Group type: EXPERIMENTAL
Intervention: (68)Ga-PRGD2 PET/CT
Number of subjects: 20

Group type: COMPARATOR
Intervention: (18)F-FDG PET/CT
Number of subjects: 20
Study: 24532785

Group type: EXPERIMENTAL
Intervention: Natalizumab (Tysabri)
Number of subjects: 4821
Study: 24532956

Group type: EXPERIMENTAL
Intervention: Phosribbon(®)
Number of subjects: 16
Study: 24533707

Group type: EXPERIMENTAL
Intervention: COMT SNPs (rs6269, rs4633, rs4818, rs4680)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: COMT SNPs (rs6269, rs4633, rs4680)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Haplotype 2 (GCGG)
Number of subjects: 149
Study: 24534108

Group type: EXPERIMENTAL
Intervention: 5-azacitidine (75 mg/m² for 5 to 7 days every 4 weeks until a suitable donor was found)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Allogeneic HCT after myeloablative pharmacokinetically targeted i.v. busulfan and fludarabine conditioning regimen
Number of subjects: 25
Study: 24534109

Group type: EXPERIMENTAL
Intervention: Chemosensitive patients according to CT criteria
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: FDG-PET-positive patients (Deauville 4 to 5, n = 24)
Number of subjects: 88

Group type: COMPARATOR
Intervention: FDG-PET-negative patients (Deauville 1 to 3, n = 34)
Number of subjects: 88
Study: 24534286

Group type: EXPERIMENTAL
Intervention: Polycystic ovary syndrome (PCOS)
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Hyperprolactinemia
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Premature ovarian failure
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Serum total testosterone level and free androgen index
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Androstenedione and dehydroepiandrosterone sulfate (DHEAS)
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Low age of menarche, high levels of high-sensitivity C-reactive protein and liver enzymes, low levels of sex hormone-binding globulin
Number of subjects: 573
Study: 24535278

Group type: EXPERIMENTAL
Intervention: Maraviroc plus raltegravir
Number of subjects: 44
Study: 24535655

Group type: EXPERIMENTAL
Intervention: HIV-infected subjects
Number of subjects: 143
Study: 24548045

Group type: EXPERIMENTAL
Intervention: Metformin plus lifestyle intervention
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Baseline parent-youth verbal conflict
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Parent-youth verbal conflict at 6 months
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Parent-youth verbal conflict at 12 months
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Parent-youth conflict
Number of subjects: 137
Study: 24548643

Group type: EXPERIMENTAL
Intervention: 250 ml white wine (25 g alcohol) daily for 6 weeks
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 660 ml beer (26 g alcohol) daily for 3 weeks
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 100 ml vodka (30 g alcohol) daily for 4 weeks
Number of subjects: 84

Group type: COMPARATOR
Intervention: white grape juice daily for 6 weeks
Number of subjects: 84

Group type: COMPARATOR
Intervention: alcohol-free beer daily for 3 weeks
Number of subjects: 84

Group type: COMPARATOR
Intervention: only orange juice daily for 4 weeks
Number of subjects: 84
Study: 24549158

Group type: EXPERIMENTAL
Intervention: Smoking of a current close friend
Number of subjects: 2586

Group type: EXPERIMENTAL
Intervention: Smoking of a close friend during schooldays
Number of subjects: 2586

Group type: EXPERIMENTAL
Intervention: Smoking behaviour of mothers and siblings (for men)
Number of subjects: 2586

Group type: EXPERIMENTAL
Intervention: Smoking behaviour of mothers and siblings (for women)
Number of subjects: 2586
Study: 24550219

Group type: EXPERIMENTAL
Intervention: Short-term intensive insulin therapy (IIT) consisting of basal insulin detemir and premeal insulin aspart for 4 weeks
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Short-term intensive insulin therapy (IIT)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Patients with an increase in ISSI-2 ≥25%
Number of subjects: 61
Study: 24552242

Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 2164
Study: 24552750

Group type: EXPERIMENTAL
Intervention: Higher biomarker-calibrated protein intake (15% of energy intake)
Number of subjects: 144580
Study: 24552754

Group type: EXPERIMENTAL
Intervention: Total sugars
Number of subjects: 353751

Group type: EXPERIMENTAL
Intervention: Total fructose
Number of subjects: 353751

Group type: EXPERIMENTAL
Intervention: Added fructose
Number of subjects: 353751

Group type: EXPERIMENTAL
Intervention: Added sugars
Number of subjects: 353751

Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 353751

Group type: EXPERIMENTAL
Intervention: Added sucrose
Number of subjects: 353751
Study: 24554062

Group type: EXPERIMENTAL
Intervention: Neoadjuvant sorafenib (dose escalation cohort 1: 200 mg twice daily, cohort 2: 200/400 mg daily) plus preoperative conformal radiotherapy (50 Gy in 25 fractions)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Neoadjuvant sorafenib plus RT
Number of subjects: 8
Study: 24555130

Group type: EXPERIMENTAL
Intervention: Novel semiautomated grading system (RetmarkerAMD)
Number of subjects: 89
Study: 24555562

Group type: EXPERIMENTAL
Intervention: Women with COPD
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Chronic sputum in women
Number of subjects: 430

Group type: COMPARATOR
Intervention: Men with COPD
Number of subjects: 430
Study: 24555723

Group type: EXPERIMENTAL
Intervention: BK0023
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neupogen®
Number of subjects: 0
Study: 24557359

Group type: EXPERIMENTAL
Intervention: Midstromal implant of an isolated Bowman layer graft
Number of subjects: 9
Study: 24557701

Group type: EXPERIMENTAL
Intervention: SPAN-100-positive patients
Number of subjects: 202

Group type: COMPARATOR
Intervention: SPAN-100-negative patients
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: SPAN-100-positive status
Number of subjects: 202
Study: 24558033

Group type: COMPARATOR
Intervention: Low dose naltrexone (4.5 mg/day) for 12 weeks in adults
Number of subjects: 46

Group type: COMPARATOR
Intervention: Low dose naltrexone (0.1 mg/kg, maximum 4.5 mg/day) for 8 weeks in children
Number of subjects: 46

Group type: COMPARATOR
Intervention: Low dose naltrexone and placebo
Number of subjects: 46
Study: 24558173

Group type: EXPERIMENTAL
Intervention: Significant obstructive sleep apnoea (OSA) defined as an apnoea/hypopnoea index ≥ 20 events·h(-1)
Number of subjects: 84

Group type: COMPARATOR
Intervention: No significant obstructive sleep apnoea (OSA)
Number of subjects: 84
Study: 24558979

Group type: EXPERIMENTAL
Intervention: HPV positive samples from women with ICC
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: HPV types detected in ICC cases
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Histological diagnosis of cervical samples
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Type of cervical cancer diagnosed
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Co-infection recorded
Number of subjects: 114
Study: 24559067

Group type: EXPERIMENTAL
Intervention: Wobenzym (hydrolytic enzymes: bromelain, trypsin; flavonoid: rutoside)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 24559258

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 64
Study: 24559321

Group type: EXPERIMENTAL
Intervention: Intravenous anidulafungin followed by oral azole therapy (fluconazole or voriconazole) after 5 days if criteria met
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Early switch to oral azole therapy (≤ 7 days' anidulafungin)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Intravenous anidulafungin followed by oral azole therapy
Number of subjects: 250
Study: 24559465

Group type: EXPERIMENTAL
Intervention: Urinary [TIMP-2]·[IGFBP7] greater than 0.3 (ng/ml)(2)/1,000
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Urinary [TIMP-2]·[IGFBP7]
Number of subjects: 420
Study: 24559784

Group type: EXPERIMENTAL
Intervention: EUS-FNA
Number of subjects: 51

Group type: COMPARATOR
Intervention: ERCP tissue sampling
Number of subjects: 51
Study: 24559803

Group type: COMPARATOR
Intervention: (18)F-fluorodeoxyglucose (18F-FDG) PET/CT
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Whole-body diffusion-weighted MRI
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Comparison of both imaging modalities
Number of subjects: 22